| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | n/a | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | n/a | n/a |
| Pr/Book | 3.2 |
| Latest | F'cast | |
|---|---|---|
| Revenue | n/a | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-20 | n/a | (2.67) | 0.00¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-21 | n/a | (1.79) | (0.13)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | n/a | (2.61) | (0.19)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 0.04 | (0.20) | (1,225.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | n/a | (0.59) | (0.01)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| US Orphan Drug Designation Application | 30-Oct-2025 | 07:00 | RNS |
| Positive Preclinical Data in Prostate Cancer | 14-Oct-2025 | 07:00 | RNS |
| Half Year Report | 15-Sep-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 11.75p |
| Change Today | 1.25p |
| % Change | 11.90 % |
| 52 Week High | 12.50 |
| 52 Week Low | 10.50 |
| Volume | 328,061 |
| Shares Issued | 39.96m |
| Market Cap | £4.70m |
| Value |
|
|---|
| Value |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| Latest | Previous | |
|---|---|---|
| Special | Interim | |
| Ex-Div | 01-Jun-23 | n/a |
| Paid | 14-Jun-23 | n/a |
| Amount | 1.80p | 0.000¢ |
| Time | Volume / Share Price |
| 16:28 | 25,000 @ 12.42p |
| 16:22 | 1,900 @ 12.42p |
| 15:53 | 10,000 @ 12.43p |
| 15:28 | 1,571 @ 12.47p |
| 14:52 | 40 @ 12.50p |
| CEO | Andrew James Webb |
You are here: research